Cablivi – Kaplacizumab uses, dose and side effects
Cablivi contains the active substance caplacizumab. It is used to treat an episode of acquired thrombotic thrombocytopenic purpura in adults and adolescents 12 years of age and older weighing at least 40 kg. This is a rare coagulation disease in which blood clots form in small blood vessels. These blood clots can block blood vessels and damage the brain, heart, kidneys, or other organs. Cablivi prevents the formation of these blood clots by preventing the platelets (platelets) in the blood from clotting. In this way, Cablivi reduces the risk of a new episode of acquired thrombotic thrombocytopenia purpura (aTTP) shortly after the first.
Read More